UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): June 29, 2021
USA EQUITIES CORP.
(Exact Name of Registrant as Specified in its Charter)
0-19041
(Commission File No.)
Delaware | 30-1104301 | |
(State of Incorporation) |
(I.R.S. Employer Identification No.) | |
901 Northpoint Parkway Suite 302 West Palm Beach FL 33407 |
33407 | |
(Address of Principal Executive Offices) | (ZIP Code) |
Registrant’s telephone number, including area code: (929) 379-6503
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Common Stock, $0.0001 par value | USAQ | OTCMKTS |
Item 7.01 Regulation FD Disclosure.
On June 29, 2021, USA Equities Corp. (the “Company”) issued a press release entitled “USA Equities Corp Announces the signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services.”
A copy of the above-mentioned press release is attached herewith as Exhibit 99.1.
By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website (https://usaqcorp.com), press releases, and various social media channels, including its Twitter account (https://twitter.com/USAQcorp), its LinkedIn account (https://www.linkedin.com/company/usaqcorp) its Facebook account (https://www.facebook.com/USA-Equities-100113722270622), and its Instagram account (https://www.instagram.com/usaqcorp/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.
ITEM 9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: June 29, 2021 | ||
USA Equities Corp. | ||
/s/ Troy Grogan | ||
Name: | Troy Grogan | |
Title: | CEO and Chairman |
EXHIBIT 99.1
USA Equities Corp Announces the Signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services
-Continued Momentum Expanding Independent Care Practitioner Network-
West Palm Beach, FL – June 29, 2021 – USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, today announced it has entered into a distribution agreement with a prominent physician management services organization (MSO) for its AllergiEnd® allergy diagnostic and allergen immunotherapy products and services. The MSO will facilitate the working relation between USAQ and its physician members, as well as provide marketing and advertising support. Given the size of the MSO’s member roster, the roll out will be done in stages so as to ensure adequate training and staff support.
“Today’s announcement is further evidence of our continued progress and momentum as we expand our independent medical provider practice network. The growing interest in AllergiEnd®’s allergy diagnostic services and allergen immunotherapy products reflects the attractiveness of our value-based tools to proactively address chronic disease, provide preventive care as well as enable the broad market of general practitioner physicians to broaden their practices and revenue base,” said Troy Grogan, CEO of USA Equities Corp.
“Our new distributor relationship announced today has a significant growing national physician customer base and footprint which offers us a strong platform from which to increase our base of clients and over time potentially launch additional products. We are entering the second half of fiscal 2021 very well positioned and highly energized to grow our client and recurring revenue base, continue to increase our industry visibility and progress our work to expand our product portfolio as we further execute on our growth strategy,” concluded Grogan.
About USA Equities Corp.
USA Equities Corp. (OTCQB: USAQ) is focused on providing value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior-based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow general practice physicians and other medical practitioners to increase revenues by cost effectively diagnosing and treating chronic diseases that are generally referred to specialists. The Company’s products and information service portfolio are directed toward prevention, early detection, management and reversal of allergies, cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, point of care devices and approaches, providing more granular, timely and specific clinical decision-making information for practicing physicians and other health care providers to address today’s allergy prone, obese, diabetic and cardiovascular disease population.
For additional information, visit the Company’s website at www.USAQCorp.com
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products and the acceptance of these products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor & Media Contact: | |
Olivia Giamanco | |
USA Equities Corp | |
(929) 379-6503 | |
IR@USAQCORP.COM |
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